Literature DB >> 33941265

Public and private sectors collective response to combat COVID-19 in Malaysia.

Ching Siang Tan1, Saim Lokman2, Yao Rao3, Szu Hua Kok4, Long Chiau Ming5.   

Abstract

Over the last year, the dangerous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly around the world. Malaysia has not been excluded from this COVID-19 pandemic. The resurgence of COVID-19 cases has overwhelmed the public healthcare system and overloaded the healthcare resources. Ministry of Health (MOH) Malaysia has adopted an Emergency Ordinance (EO) to instruct private hospitals to receive both COVID-19 and non-COVID-19 patients to reduce the strain on public facilities. The treatment of COVID-19 patients at private hospitals could help to boost the bed and critical care occupancy. However, with the absence of insurance coverage because COVID-19 is categorised as pandemic-related diseases, there are some challenges and opportunities posed by the treatment fees management. Another major issue in the collaboration between public and private hospitals is the willingness of private medical consultants to participate in the management of COVID-19 patients, because medical consultants in private hospitals in Malaysia are not hospital employees, but what are termed "private contractors" who provide patient care services to the hospitals. Other collaborative measures with private healthcare providers, e.g. tele-conferencing by private medical clinics to monitor COVID-19 patients and the rollout of national vaccination programme. The public and private healthcare partnership must be enhanced, and continue to find effective ways to collaborate further to combat the pandemic. The MOH, private healthcare sectors and insurance providers need to have a synergistic COVID-19 treatment plans to ensure public as well as insurance policy holders have equal opportunities for COVID-19 screening tests, vaccinations and treatment.

Entities:  

Keywords:  COVID-19; Collaborative measures; Insurance providers; Ministry of Health Malaysia; Private healthcare sectors

Year:  2021        PMID: 33941265     DOI: 10.1186/s40545-021-00322-x

Source DB:  PubMed          Journal:  J Pharm Policy Pract        ISSN: 2052-3211


  5 in total

1.  Assessing the Impact of Out-of-Pocket Expenditures for Prevention of COVID-19 Infection on Households: Evidence From Malaysia.

Authors:  Hafiz Jaafar; Nur Amalina Abd Laziz; Muslimah Ithnin; Amirah Azzeri
Journal:  Inquiry       Date:  2021 Jan-Dec       Impact factor: 1.730

2.  The Impact of COVID-19 on Hospital Admissions for Twelve High-Burden Diseases and Five Common Procedures in the Philippines: A National Health Insurance Database Study 2019-2020.

Authors:  Jhanna Uy; Vanessa T Siy Van; Valerie Gilbert Ulep; Diana Beatriz Bayani; Damian Walker
Journal:  Lancet Reg Health West Pac       Date:  2021-11-03

3.  Sustaining effective COVID-19 control in Malaysia through large-scale vaccination.

Authors:  Pavithra Jayasundara; Kalaiarasu M Peariasamy; Kian Boon Law; Ku Nurhasni Ku Abd Rahim; Sit Wai Lee; Izzuna Mudla M Ghazali; Milinda Abayawardana; Linh-Vi Le; Rukun K S Khalaf; Karina Razali; Xuan Le; Zhuo Lin Chong; Emma S McBryde; Michael T Meehan; Jamie M Caldwell; Romain Ragonnet; James M Trauer
Journal:  Epidemics       Date:  2021-10-26       Impact factor: 5.324

4.  Compliance to Infection Prevention and Control Practices Among Healthcare Workers During COVID-19 Pandemic in Malaysia.

Authors:  Nadia Mohamad; Muhammad Alfatih Pahrol; Rafiza Shaharudin; Nik Khairol Reza Md Yazin; Yelmizaitun Osman; Haidar Rizal Toha; Normazura Mustapa; Zuraida Mohamed; Azyyati Mohammad; Rohaida Ismail
Journal:  Front Public Health       Date:  2022-07-18

5.  The Impact of the COVID-19 Pandemic on Physicians' Working Hours and Earnings in São Paulo and Maranhão States, Brazil.

Authors:  Bruno Luciano Carneiro Alves de Oliveira; Lucas Salvador Andrietta; Regimarina Soares Reis; Ruth Helena de Souza Britto Ferreira de Carvalho; Maria Teresa Seabra Soares de Britto E Alves; Mário César Scheffer; Giuliano Russo
Journal:  Int J Environ Res Public Health       Date:  2022-08-15       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.